GO:0019772 low-affinity IgG receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019772 low-affinity IgG receptor activity describes the molecular function of binding IgG antibodies via their Fc region with low affinity and transmitting a signal across the membrane to change cell behavior.
• The best-characterized low-affinity IgG receptors are FcγRIIA (CD32A) and FcγRIIB (CD32B), which differ in signaling: FcγRIIA carries an immunoreceptor tyrosine-based activation motif (ITAM), while FcγRIIB carries an immunoreceptor tyrosine-based inhibitory motif (ITIM).
• The H131R polymorphism in FCGR2A (rs1801274) alters IgG binding affinity and has been associated with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus.
• Low-affinity IgG receptors are central to anaphylaxis, allergy, and immune complex diseases, as shown by human low-affinity IgG receptor locus knock-in mouse models and studies of allergen-specific IgG.
• FcγRIIB can deliver inhibitory signals that suppress allergic inflammation, and low-affinity allergen-specific IgG can be protective through this receptor.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of FCGR2A, FCGR2B, and related genes in immune signaling and disease.
Description
GO:0019772 low-affinity IgG receptor activity is a molecular function defined as combining with low affinity with an immunoglobulin of the IgG isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. This activity is mediated by Fc gamma receptors (FcγRs) that recognize the Fc portion of IgG antibodies, and it is a key mechanism by which antibodies bridge humoral immunity and cellular effector responses. Unlike high-affinity receptors such as FcγRI (CD64), low-affinity IgG receptors require multivalent immune complexes for efficient engagement, making them sensitive to antibody density and immune complex size. The best-studied low-affinity IgG receptors are FcγRIIA (CD32A) and FcγRIIB (CD32B), which are encoded by FCGR2A and FCGR2B, respectively. FcγRIIA is an activating receptor that signals through an immunoreceptor tyrosine-based activation motif (ITAM), whereas FcγRIIB is an inhibitory receptor that signals through an immunoreceptor tyrosine-based inhibitory motif (ITIM). This functional dichotomy allows low-affinity IgG receptors to fine-tune immune responses, balancing activation and inhibition. Low-affinity IgG receptor activity is important for researchers because it contributes to host defense, autoimmunity, allergy, and anaphylaxis. For example, the FCGR2A H131R polymorphism has been linked to subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus, and human low-affinity IgG receptor locus knock-in mice have revealed mechanisms of anaphylaxis. Understanding this activity at the molecular, cellular, and organismal levels can inform therapeutic strategies targeting FcγRs in inflammatory and autoimmune diseases.
low-affinity IgG receptor activity At A Glance
| GO ID | GO:0019772 |
|---|---|
| GO term | low-affinity IgG receptor activity |
| Ontology | molecular_function |
| Synonym | low affinity Fc receptor activity; low affinity IgG receptor activity |
| Major function | Binding IgG via the Fc region with low affinity and transmitting a signal across the membrane to initiate a change in cell activity |
| Representative receptors | FcγRIIA (CD32A) and FcγRIIB (CD32B) |
| Signaling motifs | ITAM for activating receptors such as FcγRIIA; ITIM for inhibitory receptors such as FcγRIIB |
| Ligand | Immunoglobulin G (IgG) isotype antibodies, particularly in immune complexes |
| Cellular context | Expressed on immune cells including platelets, macrophages, B cells, and mast cells |
What Is GO:0019772?
In our own words, GO:0019772 low-affinity IgG receptor activity refers to the ability of a cell-surface receptor to bind the Fc region of IgG antibodies with low affinity and, upon binding, transmit a signal across the plasma membrane that leads to a change in cell behavior. This activity is typically mediated by Fc gamma receptors such as FcγRIIA and FcγRIIB, which engage IgG-containing immune complexes and initiate intracellular signaling cascades. The low-affinity nature means that monovalent IgG binding is weak, and efficient receptor engagement usually requires multivalent interactions, such as those found in immune complexes or on opsonized surfaces.
Why Is low-affinity IgG receptor activity Important in Cell Biology?
Low-affinity IgG receptor activity is critically important because it links antibody recognition to cellular effector functions, thereby shaping immune responses in health and disease. These receptors enable cells to detect IgG-opsonized targets and immune complexes, triggering processes such as phagocytosis, cytokine release, and platelet activation. Dysregulation of this activity contributes to autoimmune diseases like systemic lupus erythematosus, allergic disorders, and anaphylaxis. Moreover, the balance between activating and inhibitory low-affinity IgG receptors determines the outcome of immune complex-mediated inflammation, making these receptors attractive therapeutic targets.
• Low-affinity IgG receptors mediate antibody-dependent cellular effector functions, including phagocytosis and cytokine release.
• The FCGR2A H131R polymorphism affects IgG binding affinity and is associated with subclinical atherosclerosis and platelet hyperactivity in SLE.
• FcγRIIB provides inhibitory signals that can suppress allergic inflammation and autoimmunity.
• Low-affinity IgG receptors are involved in anaphylaxis, as demonstrated by human low-affinity IgG receptor locus knock-in mouse models.
• Allergen-specific IgG can be protective through FcγRIIB, highlighting the therapeutic potential of targeting this receptor.
• Platelet FcγRIIA contributes to thrombosis and inflammatory responses in autoimmune settings.
• BAFF inhibition in SLE may restore tolerance partly by modulating FcγR-mediated pathways.
• Antibodies can act as natural adjuvants by engaging low-affinity IgG receptors on antigen-presenting cells.
• Understanding low-affinity IgG receptor activity aids in the design of vaccines and antibody therapeutics.
• CRISPR-based models enable precise interrogation of FCGR2A and FCGR2B functions in disease.
Molecular Mechanism of low-affinity IgG receptor activity
Ligand Binding and Receptor Engagement
In simple terms: The receptor grabs onto the tail of an IgG antibody, but only weakly, so it needs many antibodies clustered together to hold on tightly.
Low-affinity IgG receptors such as FcγRIIA and FcγRIIB bind the Fc region of IgG antibodies with low affinity, meaning that monovalent IgG binding is weak and efficient engagement typically requires multivalent immune complexes. This low affinity allows the receptors to discriminate between monomeric IgG and aggregated IgG in immune complexes, ensuring that signaling occurs primarily in the presence of opsonized targets or immune complexes. The binding specificity is determined by the receptor's extracellular immunoglobulin-like domains, which interact with the CH2-CH3 hinge region of IgG.
Signaling Motifs and Intracellular Transduction
In simple terms: Once the receptor binds IgG, it sends a signal inside the cell either by adding phosphate tags (activation) or by removing them (inhibition).
FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic tail, which becomes phosphorylated upon receptor clustering, leading to recruitment and activation of Syk and downstream signaling cascades. In contrast, FcγRIIB contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) that recruits SHIP and SHP phosphatases to dampen activating signals. This ITAM/ITIM dichotomy allows low-affinity IgG receptors to either promote or suppress cellular responses depending on the receptor engaged.
Cellular Responses and Effector Functions
In simple terms: The signal makes the cell do something, like gobble up targets, release inflammatory chemicals, or change its behavior.
Activation of low-affinity IgG receptors can trigger a variety of cellular responses, including phagocytosis, degranulation, cytokine production, and platelet activation. For example, FcγRIIA on platelets mediates platelet activation and aggregation in response to IgG immune complexes, contributing to thrombosis in autoimmune diseases. In mast cells, low-affinity IgG receptors can induce anaphylaxis through the release of mediators. Inhibitory signaling through FcγRIIB can suppress these responses, maintaining immune homeostasis.
Regulation by Immune Complexes and Antibody Glycosylation
In simple terms: The strength of the signal depends on how many antibodies are clustered and what sugar tags they carry.
The extent of low-affinity IgG receptor activation is influenced by the size and composition of immune complexes, as well as the glycosylation state of the IgG Fc region. Antibody glycosylation can modulate binding to FcγRs, thereby tuning effector functions. Additionally, the balance between activating and inhibitory receptors on a given cell determines the net outcome of receptor engagement.
Genetic Variation and Receptor Polymorphisms
In simple terms: Small changes in the receptor's DNA sequence can alter how well it binds IgG and affect disease risk.
The FCGR2A H131R polymorphism (rs1801274) changes the amino acid at position 131 from histidine to arginine, affecting the receptor's affinity for IgG subclasses. This polymorphism has been associated with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus, illustrating how genetic variation in low-affinity IgG receptors can influence disease susceptibility. Similar polymorphisms in FCGR2B may also affect inhibitory signaling and autoimmune risk.
Key Genes Involved in GO:0019772 low-affinity IgG receptor activity
The following genes encode the major low-affinity IgG receptors and related signaling molecules that mediate GO:0019772 low-affinity IgG receptor activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FCGR2A | Encodes FcγRIIA (CD32A), an activating low-affinity IgG receptor with an ITAM | Target for studying platelet activation, SLE, and atherosclerosis; H131R polymorphism affects IgG binding |
| FCGR2B | Encodes FcγRIIB (CD32B), an inhibitory low-affinity IgG receptor with an ITIM | Key mediator of inhibitory signaling in allergy and autoimmunity; target for therapeutic enhancement |
| FCGR2C | Encodes FcγRIIc, a low-affinity IgG receptor with activating potential | Expressed on NK cells and involved in antibody-dependent cellular cytotoxicity |
| FCGR3A | Encodes FcγRIIIA (CD16a), a low-affinity IgG receptor associated with FcεRIγ or CD3ζ | Mediates NK cell activation and antibody-dependent cellular cytotoxicity |
| FCGR3B | Encodes FcγRIIIB (CD16b), a GPI-anchored low-affinity IgG receptor on neutrophils | Involved in neutrophil activation and immune complex clearance |
| SYK | Spleen tyrosine kinase, recruited to phosphorylated ITAMs of FcγRIIA | Central kinase in activating FcγR signaling; target for inhibitor studies |
| SHIP1 | Inositol polyphosphate-5-phosphatase, recruited to phosphorylated ITIMs of FcγRIIB | Mediates inhibitory signaling; knockout models show enhanced activation |
| SHP1 | Protein tyrosine phosphatase, recruited to ITIMs of FcγRIIB | Dampens activating signals; relevant to autoimmunity |
| LYN | Src-family kinase that phosphorylates ITAMs and ITIMs | Regulates both activating and inhibitory FcγR signaling |
| PLCG2 | Phospholipase C gamma 2, downstream of ITAM signaling | Mediates calcium flux and cellular activation |
| PIK3CD | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta, downstream of FcγR signaling | Involved in immune cell activation and survival |
| CARD9 | Adapter protein downstream of ITAM signaling in myeloid cells | Links FcγR signaling to NF-κB activation |
| TNF | Pro-inflammatory cytokine induced by FcγR activation | Readout of macrophage activation via low-affinity IgG receptors |
| IL6 | Cytokine produced upon FcγRIIA activation | Marker of inflammatory responses in autoimmune models |
| BAFF | B-cell activating factor, modulates B cell survival and FcγRIIB expression | Therapeutic target in SLE; linked to tolerance restoration |
| FOXP3 | Transcription factor in regulatory T cells and macrophages | Modulates inflammatory responses in stroke; potential crosstalk with FcγR signaling |
| C1Q | Complement component that interacts with immune complexes and FcγRs | Influences immune complex clearance and FcγR engagement |
How Is low-affinity IgG receptor activity Regulated?
Low-affinity IgG receptor activity is regulated at multiple levels, including receptor expression, post-translational modifications, and the availability of ligands. The balance between activating and inhibitory receptors on a cell surface determines the net signaling outcome. Cytokines such as BAFF can modulate B cell survival and FcγRIIB expression, influencing tolerance and autoimmunity. Additionally, antibody glycosylation and immune complex size regulate receptor engagement and downstream signaling. Phosphorylation of ITAM and ITIM motifs by Src-family kinases such as LYN is a key regulatory step. Phosphatases like SHIP1 and SHP1 terminate or dampen signals, preventing excessive inflammation.
low-affinity IgG receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FCGR2A | Systemic lupus erythematosus, atherosclerosis, platelet hyperactivity | Knock-in mouse expressing H131R variant; platelet aggregation assays |
| FCGR2B | Allergy, autoimmunity, anaphylaxis | Knockout mouse or humanized FcγRIIB knock-in; allergy models |
| FCGR3A | Antibody-dependent cellular cytotoxicity in cancer and viral infection | NK cell knockout or overexpression models; cytotoxicity assays |
| BAFF | SLE, B cell tolerance | BAFF transgenic or knockout mice; B cell survival assays |
| FOXP3 | Ischemic stroke, neuroinflammation | Conditional knockout mice; stroke models |
Systemic Lupus Erythematosus and Atherosclerosis
The FCGR2A H131R polymorphism has been associated with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus, suggesting that altered low-affinity IgG receptor function contributes to cardiovascular complications in autoimmune disease. Platelet FcγRIIA mediates activation in response to IgG immune complexes, promoting thrombosis. BAFF inhibition is being explored as a therapeutic strategy in SLE to restore tolerance, potentially by modulating FcγR-mediated pathways.
Allergy and Anaphylaxis
Low-affinity IgG receptors play a central role in anaphylaxis, as demonstrated by human low-affinity IgG receptor locus knock-in mouse models. Allergen-specific IgG can be protective through the inhibitory receptor FcγRIIB, which suppresses allergic inflammation. The effector function of allergens is influenced by their ability to engage FcγRs, and understanding these interactions may inform allergy therapies.
Inflammatory and Neurological Conditions
FOXP3+ macrophages can repress acute ischemic stroke-induced neural inflammation, and this process may involve modulation of FcγR signaling. Antibodies acting as natural adjuvants can enhance immune responses via low-affinity IgG receptors, linking these receptors to vaccine efficacy and inflammatory diseases.
From low-affinity IgG receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FCGR2A H131R alter IgG binding and platelet activation? | Point-mutation knock-in of FCGR2A H131R in human cell lines or mice |
| What is the role of FcγRIIB in suppressing allergic inflammation? | FCGR2B knockout or humanized knock-in mouse; allergy models |
| How does FcγRIIA signaling drive cytokine release? | FCGR2A knockout and overexpression in macrophages; cytokine profiling |
| Can FcγRIIB activation be therapeutically enhanced? | Knock-in mice with FcγRIIB-specific mutations; therapeutic antibody testing |
| What is the impact of FCGR2A/FCGR2B on SLE tolerance? | CRISPR knockout of FCGR2A/FCGR2B in B cells; autoantibody assays |
| How do low-affinity IgG receptors contribute to anaphylaxis? | Human low-affinity IgG receptor locus knock-in mice; passive anaphylaxis models |
How to Study the low-affinity IgG receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics of FcγR-IgG interactions | Characterizing low-affinity binding and polymorphism effects |
| Phospho-Western blot | Phosphorylation of ITAM/ITIM and downstream kinases | Assessing receptor activation and signaling |
| Platelet aggregation assay | Platelet activation via FcγRIIA | Studying thrombosis in SLE and atherosclerosis |
| Cytokine release assay | Production of TNF, IL-6 upon FcγR activation | Macrophage and immune cell activation studies |
| Flow cytometry | Receptor surface expression and immune complex binding | Phenotyping cells and assessing receptor levels |
| CRISPR knockout screen | Identification of genes regulating FcγR signaling | Discovery of novel modulators and drug targets |
| Passive anaphylaxis model | In vivo anaphylaxis mediated by low-affinity IgG receptors | Testing therapeutic interventions in knock-in mice |
| BAFF inhibition assay | B cell survival and tolerance restoration | Evaluating SLE therapeutics |
Surface Plasmon Resonance and Affinity Measurements
Surface plasmon resonance (SPR) and related biophysical methods can measure the binding affinity of low-affinity IgG receptors to IgG subclasses and Fc variants. These techniques are essential for characterizing the low-affinity nature of FcγRIIA and FcγRIIB and for assessing the impact of polymorphisms such as H131R.
Phospho-Specific Signaling Assays
Western blotting with phospho-specific antibodies against ITAM and ITIM motifs, as well as downstream kinases like Syk, can reveal activation of low-affinity IgG receptor signaling. These assays are used to study the kinetics of receptor phosphorylation and the balance between activating and inhibitory pathways.
Functional Cellular Assays
Platelet aggregation, degranulation, phagocytosis, and cytokine release assays are used to measure the functional consequences of low-affinity IgG receptor engagement. These assays can be performed with primary cells or cell lines expressing wild-type or mutant receptors.
CRISPR-Based Genetic Screens
CRISPR knockout and knock-in screens can identify genes that modulate low-affinity IgG receptor activity and downstream signaling. Such screens are valuable for discovering novel regulators and therapeutic targets in autoimmune and allergic diseases.
How CRISPR Can Be Used to Study GO:0019772 low-affinity IgG receptor activity
Knockout
CRISPR knockout of FCGR2A or FCGR2B in immune cell lines or primary cells can abolish low-affinity IgG receptor activity, allowing researchers to study the specific contributions of each receptor to signaling and disease. For example, FCGR2A knockout platelets show reduced aggregation in response to IgG immune complexes.
Point Mutation
CRISPR point mutation can introduce the H131R variant into FCGR2A to mimic the human polymorphism associated with SLE and atherosclerosis. Such models enable precise assessment of how a single amino acid change alters IgG binding affinity and cellular responses.
Knock-in
Knock-in of human low-affinity IgG receptor loci into mice, as demonstrated by Gillis et al., allows in vivo study of anaphylaxis and immune complex diseases. This approach preserves physiological expression patterns and regulatory elements, providing a more accurate model than transgenic overexpression.
Overexpression
Overexpression of FCGR2A or FCGR2B in cell lines can enhance receptor signaling and facilitate biochemical studies of downstream pathways. However, overexpression may saturate signaling and should be interpreted with caution; knock-in models are preferred for physiological relevance.
How EDITGENE Supports low-affinity IgG receptor activity Research
Researchers studying low-affinity IgG receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, immune complex clearance, or disease pathogenesis. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation of genes such as FCGR2A, FCGR2B, and their signaling partners.
Contact EDITGENE today to design your custom CRISPR model for low-affinity IgG receptor activity research.
Frequently Asked Questions About low-affinity IgG receptor activity
What is low-affinity IgG receptor activity?
Low-affinity IgG receptor activity (GO:0019772) is the molecular function of binding IgG antibodies via their Fc region with low affinity and transmitting a signal across the membrane to initiate a change in cell activity.
What genes are involved in low-affinity IgG receptor activity?
Key genes include FCGR2A (FcγRIIA), FCGR2B (FcγRIIB), FCGR2C, FCGR3A, and FCGR3B, which encode low-affinity Fc gamma receptors.
What is the difference between FcγRIIA and FcγRIIB?
FcγRIIA is an activating receptor with an ITAM, while FcγRIIB is an inhibitory receptor with an ITIM; they mediate opposing signals upon IgG binding.
How does the FCGR2A H131R polymorphism affect disease?
The H131R polymorphism alters IgG binding affinity and has been associated with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus.
What role do low-affinity IgG receptors play in anaphylaxis?
Human low-affinity IgG receptor locus knock-in mice have demonstrated that these receptors can mediate anaphylaxis, highlighting their role in severe allergic reactions.
Can low-affinity IgG receptors be inhibitory?
Yes, FcγRIIB is an inhibitory low-affinity IgG receptor that suppresses activating signals and can protect against allergic inflammation.
How are low-affinity IgG receptors studied in the lab?
Common methods include surface plasmon resonance for binding affinity, phospho-Western blots for signaling, and functional assays such as platelet aggregation and cytokine release.
What diseases are linked to low-affinity IgG receptor activity?
They are linked to systemic lupus erythematosus, atherosclerosis, allergy, anaphylaxis, and other immune complex-mediated conditions.
Can CRISPR be used to study low-affinity IgG receptors?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect the functions of FCGR2A, FCGR2B, and related genes.
What is the therapeutic potential of targeting low-affinity IgG receptors?
Modulating these receptors, especially enhancing FcγRIIB inhibitory signaling, is a promising strategy for treating autoimmune and allergic diseases.
Conclusion
GO:0019772 low-affinity IgG receptor activity is a fundamental molecular function that enables cells to sense IgG antibodies and mount appropriate effector responses. The balance between activating and inhibitory receptors such as FcγRIIA and FcγRIIB is critical for immune homeostasis, and its dysregulation contributes to autoimmunity, allergy, and anaphylaxis. Continued research using CRISPR-based models will further elucidate the mechanisms and therapeutic potential of targeting low-affinity IgG receptors.
References
- 1. Cai W et al.. 2023. FOXP3+ macrophage represses acute ischemic stroke-induced neural inflammation.. Autophagy 19(4):1144-1163 PMID: 36170234
- 2. Clancy R et al.. 2019. Human low-affinity IgG receptor FcγRIIA polymorphism H131R associates with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus.. J Thromb Haemost 17(3):532-537 PMID: 30638300
- 3. Gillis CM et al.. 2017. Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice.. J Allergy Clin Immunol 139(4):1253-1265.e14 PMID: 27568081
- 4. Hazebrouck S et al.. 2022. The Effector Function of Allergens.. Front Allergy 3:818732 PMID: 35386644
- 5. Zha L et al.. 2018. An unexpected protective role of low-affinity allergen-specific IgG through the inhibitory receptor FcγRIIb.. J Allergy Clin Immunol 142(5):1529-1536.e6 PMID: 29391255
- 6. Qiao J et al.. 2015. The platelet Fc receptor, FcγRIIa.. Immunol Rev 268(1):241-52 PMID: 26497525
- 7. Jackson SW et al.. 2019. BAFF inhibition in SLE-Is tolerance restored?. Immunol Rev 292(1):102-119 PMID: 31562657
- 8. Heyman B. 2014. Antibodies as natural adjuvants.. Curr Top Microbiol Immunol 382:201-19 PMID: 25116101
